Th is series on Sjögren syndrome, like disease-oriented review series on systemic lupus erythematosus (SLE) [1, 2] , vasculitides, and comorbidities of rheumatic conditions [3] , consists of articles that review recent topics, bring us up to date, and provide innovative views [4] [5] [6] [7] [8] .
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Respected researchers of rheumatology and clinical immunology with a great deal of experience in this particular systemic disease provide these overviews and share their per spec tives. It is notable that the advent of innovative immune interventions in rheumatoid arthritis within the last decade and the recent approval of the anti-B cell-activat ing factor/B lymphocyte stimulator (anti-BAFF/BLyS) inhibitor belimumab for SLE have changed the lives of our patients and the treatment arma mentarium, but there is ongoing research for better therapeutic targets in Sjögren syndrome.
With this in mind, the authors of these reviews address central questions about the immunopathogenesis of Sjögren syndrome. Sipsas and colleagues [4] explore the potential role of retroviruses in initiating or maintaining disease. Vitali [5] examines the diff erences and similarities of sicca symptoms and risk of developing lymphoma between patients with HIV or hepatitis C virus infection and those with Sjögren syndrome. Low and Witte [6] investi gate the central role of type I interferons (IFNs) driving innate immunity. Youinou and Pers [7] address the obvious abnormalities of other cytokines such as BAFF/BLyS, interleukin-17, and tumor necrosis factoralpha (TNF-α) in the context of the local production in the infl amed salivary tissues.
While further insight into the pathogenesis of Sjögren syndrome in humans is of critical relevance to arrive at newer therapies, various preclinical models of either spontaneous or inducible Sjögren-like disease, as compre hensively reviewed by Delaleu and colleagues [8] , are important for testing candidate thera peutics. In this context, the advantages and disadvantages of the diff erent mice strains remind us of the diff erent models of arthritis [9] and lupus [10] . While these aspects can be discussed at length, there is a possibility that even patients with Sjögren can repre sent such heterogeneity. Moreover, Kallen berg and colleagues [11] summarize the current data from various trials studying inhibition of TNF-α, IFN-α, BAFF, and anti-CD20 and -CD22 therapy and put this in the context of what these trials have to say about the immune abnormalities in Sjögren syndrome. With the continuous initiatives of identifying patients' profi les and responses [12] , the information summarized in this review series could refl ect the current under standing of the (immuno)pathogenesis of Sjögren syn drome and the therapeutic possibilities and limita tions, which all may support our continuous search for improved therapies for this interdisciplinary disease.
